ASR Vermogensbeheer N.V. Has $2.39 Million Position in IQVIA Holdings Inc. $IQV

Key Points

• ASR Vermogensbeheer N.V. cut its IQVIA stake by 93.3% in the fourth quarter, selling 147,392 shares and ending with 10,618 shares worth about $2.39 million.
• IQVIA reported better-than-expected quarterly results, with EPS of $2.90 versus estimates of $2.83 and revenue of $4.15 billion versus $4.10 billion, while revenue rose 8.4% year over year.
• The company’s board authorized a $2.0 billion share buyback covering up to 6.8% of outstanding shares, and analysts currently rate the stock a Buy on average with a consensus target price of $225.69.

ASR Vermogensbeheer N.V. trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 93.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 10,618 shares of the medical research company's stock after selling 147,392 shares during the quarter. ASR Vermogensbeheer N.V.'s holdings in IQVIA were worth $2,393,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Ameliora Wealth Management Ltd. acquired a new position in IQVIA during the 4th quarter worth approximately $25,000. Activest Wealth Management raised its position in shares of IQVIA by 590.0% during the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company's stock worth $31,000 after purchasing an additional 118 shares during the period. Physician Wealth Advisors Inc. raised its position in shares of IQVIA by 1,340.0% during the third quarter. Physician Wealth Advisors Inc. now owns 144 shares of the medical research company's stock worth $27,000 after purchasing an additional 134 shares during the period. Westside Investment Management Inc. lifted its holdings in shares of IQVIA by 219.6% in the 3rd quarter. Westside Investment Management Inc. now owns 147 shares of the medical research company's stock worth $30,000 after purchasing an additional 101 shares in the last quarter. Finally, Measured Wealth Private Client Group LLC acquired a new stake in IQVIA in the 3rd quarter valued at $30,000. Institutional investors and hedge funds own 89.62% of the company's stock.

IQVIA Trading Down 0.1%

Shares of IQV stock opened at $178.48 on Monday. The company has a debt-to-equity ratio of 2.20, a quick ratio of 0.75 and a current ratio of 0.75. IQVIA Holdings Inc. has a 52-week low of $134.65 and a 52-week high of $247.04. The company has a market capitalization of $29.79 billion, a PE ratio of 22.12, a price-to-earnings-growth ratio of 1.72 and a beta of 1.18. The business's fifty day moving average is $170.14 and its 200 day moving average is $200.95.

IQVIA (NYSE:IQV - Get Free Report) last announced its earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts' consensus estimates of $2.83 by $0.07. The business had revenue of $4.15 billion for the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. IQVIA's quarterly revenue was up 8.4% on a year-over-year basis. During the same period last year, the firm posted $2.70 earnings per share. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts anticipate that IQVIA Holdings Inc. will post 11.5 EPS for the current fiscal year.

IQVIA announced that its board has authorized a share buyback plan on Thursday, May 7th that permits the company to buyback $2.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback plans are typically a sign that the company's leadership believes its stock is undervalued.

Analyst Ratings Changes

A number of research analysts have recently issued reports on IQV shares. Evercore reiterated an "outperform" rating and set a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. Stifel Nicolaus decreased their price objective on IQVIA from $273.00 to $220.00 and set a "buy" rating for the company in a report on Friday, February 6th. Weiss Ratings downgraded IQVIA from a "hold (c)" rating to a "hold (c-)" rating in a research note on Monday, May 4th. JPMorgan Chase & Co. cut their target price on IQVIA from $255.00 to $225.00 and set an "overweight" rating on the stock in a research report on Friday, February 6th. Finally, Truist Financial decreased their price target on IQVIA from $290.00 to $245.00 and set a "buy" rating for the company in a report on Thursday, February 19th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $225.69.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.